Article
Clinical Decision Intelligence: Which labs to order before and during peptide therapy, and how to document each decision
For peptide therapy, a defensible clinical decision has three parts: a baseline lab panel taken before the first dose, monitoring matched to the specific drug, and a written record of what you reviewed, what you decided, and why. FDA labels set monitoring guidance only for approved drugs such as semaglutide and tirzepatide. For unapproved peptides, no label or guideline exists, so your documented reasoning is the record a board will look at.
In May 2026, Alabama's Board of Medical Examiners barred licensees from prescribing, administering, recommending, or supplying research-grade peptides. In February 2026, Ohio's Board of Pharmacy summarily suspended a clinic's license over research-grade product bought from unlicensed sources. Those actions turned on what product was used and where it came from. When a board reviews a complaint about a lawful therapy, the next question is whether you can explain your clinical decisions.
That is hard to do from memory. Biomarker interpretation isn't standardized, monitoring differs by peptide family, and few practices build a decision record into the workflow. This article covers what to order, when, and how to write the decision down.
What makes a peptide prescribing decision defensible?
Three things: a baseline, monitoring matched to the drug, and a written decision record. Each depends on the one before it.
Why take a baseline before the first dose?
Take a baseline panel before the first dose; every later result is read against it. A baseline does three jobs.
It records system function. Fasting glucose, CBC with differential, lipid panel, renal function, and liver function show what the patient's metabolic, immune, endocrine, and cardiovascular systems look like before therapy.
It screens for reasons to change or stop the plan. For semaglutide (Ozempic) and tirzepatide (Mounjaro), section 8.6 of each FDA prescribing information recommends no dose adjustment for renal impairment. Both labels warn about acute kidney injury associated with volume depletion and direct clinicians to monitor renal function when adverse reactions could cause dehydration, especially during initiation or dose escalation. Checking baseline creatinine and eGFR is the author's clinical suggestion, not a universal pre-treatment lab requirement stated in these labels. Pre-existing immunosuppression changes your approach to immune-modulating peptides. Document these decisions, because the baseline shows you screened for safety before starting.
It makes later results interpretable. A creatinine of 1.2 looks normal until you know the baseline was 0.9. That is a 33% rise. The baseline shows what changed, by how much, and whether the change is expected.
Why does monitoring differ by peptide?
Peptides do not share one monitoring schedule. For GLP-1 drugs, the prescribing information gives you a starting point: renal function because of the kidney injury warning, and attention to pancreatitis symptoms. For thymosin beta-4, BPC-157, and IGF-1 analogs, no label or guideline requires any lab panel. The panels suggested below for those peptides are the author's suggestions.
One preclinical safety signal for BPC-157 comes from animal studies. FDA's July 23, 2026 PCAC presentation and briefing document reported aPTT changes in a 28-day rat and dog study. A coagulation check is an inference from that signal. It is not a requirement.
Document which approach you used for each patient and peptide, and where each choice comes from.
What should the decision record contain?
When a regulator asks you to show your clinical decision process, "I reviewed the labs and made a decision" is not enough. The record should show:
- Which biomarkers you reviewed, with dates and values
- How you interpreted them (expected, concerning, or a red flag)
- What you decided (continue, modify, pause, refer)
- Why you decided it
- How you told the patient
- What the follow-up plan was
Without that record, you are relying on memory in an audit.
Which biomarkers should you monitor for each peptide category?
Apart from the GLP-1 drugs, none of the peptides in this section is FDA-approved for the uses longevity clinics offer them for, and BPC-157 and TB-500 have no federal basis for compounding as of October 2026. Unless a label is cited, the panels and intervals below are the author's suggested protocol. They are not a label or guideline requirement, and they need sign-off from your clinical reviewer.
Which labs should you monitor on GLP-1 receptor agonists?
The semaglutide and tirzepatide labels warn about acute kidney injury from fluid loss and about acute pancreatitis. The semaglutide label reports lipase and amylase rises in trials (section 6) and tells prescribers to watch for pancreatitis symptoms (section 5.2). It does not instruct routine lipase or amylase monitoring.
Primary biomarkers (author's suggestion):
- Fasting glucose
- HbA1c
- Lipid panel (total cholesterol, LDL, HDL, triglycerides)
- Renal function (creatinine, eGFR)
Secondary biomarkers:
- Liver function tests (AST, ALT, ALP)
- Lipase, if pancreatitis is suspected
- Insulin, if abnormal at baseline
Monitoring frequency (author's suggestion):
- Baseline, before starting
- Week 4, for early response
- Week 8, the dose adjustment window
- Week 12, to decide whether to continue, modify, or pause
- Quarterly after that
Author's suggested action thresholds (not from any label or guideline):
- Creatinine rise above 15%, or an absolute rise above 0.3 mg/dL
- eGFR drop above 15%
- ALT or AST above 2 times the upper limit of normal
- Triglycerides above 300 mg/dL, or a rise above 50%
- Fasting glucose drop above 25%
Two examples of a decision note:
"Week 8: Glucose baseline 110, current 85 (23% drop). HbA1c baseline 6.8%, current 6.2%. Expected changes for this protocol at this timepoint. Decision: continue, with quarterly monitoring."
"Week 12: Creatinine baseline 1.0, current 1.18 (18% rise). Exceeds my action threshold. Patient reports a week of vomiting. Decision: pause therapy, assess hydration, refer to nephrology, recheck in 2 weeks."
Record the baseline and current values, what the comparison means clinically, and the decision you made.
Which labs should you consider for thymosin beta-4 and thymosin alpha-1?
No label or guideline sets monitoring for these peptides. The panel below is the author's suggestion.
Biomarkers to consider:
- CBC with differential (WBC count, lymphocytes, neutrophils)
- Inflammatory markers (hsCRP, ESR)
- Immunoglobulin levels (IgG, IgM, IgA), if the patient is immunocompromised at baseline
Monitoring frequency (author's suggestion): baseline, week 6, week 12, then every 6 months.
Record each result against baseline, your interpretation, and your decision. Because no published threshold exists, write down the level of change that would make you stop or refer, and have your clinical reviewer approve it.
How do you monitor BPC-157 and TB-500 with no human data?
No label or guideline sets monitoring for these peptides, and no human monitoring standard exists. The published efficacy data are from animals; one example is a rodent study available on PubMed Central. TB-500 is a synthetic fragment of thymosin beta-4, so it overlaps with the section above. It is listed here because it is usually sold and discussed alongside BPC-157.
FDA's July 23, 2026 PCAC presentation reported aPTT changes in a 28-day animal study of BPC-157, and the changes went in opposite directions: aPTT decreased in rats and increased in dogs. FDA's briefing document for the same meeting also reported triglyceride increases in female rats and dogs.
Biomarkers to consider (author's suggestion):
- CBC (hemoglobin, hematocrit, platelet count)
- Comprehensive metabolic panel, with triglycerides
- aPTT, as an inference from the FDA animal finding
- Inflammatory markers
Monitoring frequency (author's suggestion): baseline, week 8, week 12, then quarterly.
Even when labs are stable, document symptom changes in neutral terms, for example "patient-reported pain score 6/10 to 4/10." A symptom note records what the patient reported. It is not evidence that the peptide caused the change.
Which labs apply to CJC-1295, ipamorelin, and IGF-1 analogs?
No label or guideline sets monitoring for IGF-1 analogs, CJC-1295, or ipamorelin. The closest approved reference is tesamorelin (Egrifta SV), an approved growth hormone-releasing factor analog. Its FDA label says it increases IGF-1, that the effects of prolonged IGF-1 elevation are unknown, and that prescribers should monitor IGF-1 during therapy and consider stopping with persistent elevations.
Biomarkers to consider (author's suggestion):
- IGF-1
- Fasting glucose
- Renal function (creatinine, eGFR)
- Lipid panel
- Creatine kinase, if the therapy targets muscle
Monitoring frequency (author's suggestion): baseline, week 6, week 12, then every 6 months.
Record IGF-1 and glucose against baseline at each check, and the level at which you would stop. Have your clinical reviewer approve those levels.
How do you review follow-up labs step by step?
Use the same five steps at every protocol review.
Step 1: compare current labs to baseline and protocol expectations
Put the baseline and current labs side by side and identify what changed. Then ask whether the change is expected for this protocol at this timepoint.
Context matters. A glucose drop of 23% at week 8 of GLP-1 therapy is expected. A creatinine rise of 8% may be worth a recheck even though it sits under the suggested 15% action threshold.
Example: "GLP-1 protocol, week 8. Glucose baseline 110, current 85 (23% drop). HbA1c baseline 6.8%, current 6.2%. LDL down 18%, triglycerides down 12%. Creatinine stable (baseline 1.0, current 0.98). This is the expected trajectory at week 8."
Step 2: classify the findings
- Expected. The change fits the protocol's goals and timeline. Continue as planned.
- Concerning. The change is larger than expected but not yet dangerous. Monitor more often and consider a dose adjustment.
- Red flag. The value crosses your action threshold. Pause therapy, investigate, and refer if needed.
Example: "Creatinine baseline 1.0, current 1.18. This is an 18% rise. My threshold is 15%. Classification: red flag."
Step 3: document clinical reasoning and decision
Write: "Based on [biomarker changes], which indicates [clinical meaning], I am making the following decision: [action]. Reasoning: [why]."
Example: "Based on a creatinine rise of 18% and an eGFR drop to 58 after a week of vomiting, which may reflect volume depletion, a kidney risk the GLP-1 labels warn about, I am making the following decision: pause GLP-1 therapy. Reasoning: continuing risks kidney injury. Refer to nephrology for evaluation. Recheck renal function in 2 weeks."
That paragraph is the part of the chart a reviewer reads first, because it shows your reasoning at the time.
Step 4: update the treatment plan and tell the patient
Tell the patient in plain language what you decided and why.
"We reviewed your labs today. Your kidney function showed a change, so we are pausing your therapy for now and asking a kidney specialist to evaluate you. This is a safety precaution. We'll recheck your labs in 2 weeks."
Document the conversation: when you told them, how, and what you said.
Step 5: record the decision in audit-trail format
Compile:
- Date of decision
- Biomarkers reviewed, with dates and values
- Clinical interpretation
- Decision made
- How you notified the patient
- Follow-up plan
If your clinic is audited, this is the record you produce.
Why does biomarker documentation count as compliance evidence?
Regulators still act on marketing, as the FDA's warning letters to peptide sellers and the Connecticut Attorney General's actions on compounded GLP-1 marketing show. Clinical documentation is the other half of what a board reviews.
What do regulators look for?
They ask whether you can show an evidence-based clinical decision. The evidence is the biomarker data, your clinical reasoning, and a documented decision trail.
If a regulator asks why you kept a patient on therapy despite a lab finding, you need a documented answer.
The public actions in 2026, Alabama's Board notice and the Ohio Board of Pharmacy's February 2026 suspension of a clinic license, turned on what product was used and where it came from. We have not found a public order that turned on lab-monitoring records alone. Documentation still matters, because a board reviewing a complaint judges your decisions against the standard of care, and your chart is how you show what you did.
What should informed consent say about monitoring?
Before starting therapy, confirm that you:
- Disclosed the monitoring schedule for this protocol
- Discussed the lab changes you are watching for and why
- Documented that the patient understood, with signed consent
Example consent language: "You will have laboratory tests on this schedule: [insert the monitoring schedule for this protocol]. These tests check for changes that might occur with this therapy. If we see [specific red flags], we may adjust or pause your therapy. You understand and agree to this monitoring schedule."
Use the schedule from the protocol the patient is on, and have your clinical reviewer sign off on it.
Do monitoring rules vary by state?
No federal rule sets lab monitoring intervals for peptide therapy. Check whether your state medical and pharmacy boards have issued anything. Multi-state practitioners need a system that meets the strictest standard among the states they serve.
Whether or not your state specifies intervals, boards judge decisions against the standard of care: what a reasonably prudent practitioner would do in similar circumstances.
What does the audit trail show?
It answers the request to show your clinical decision process: every decision, when you made it, what data informed it, and how you communicated it to the patient.
What monitoring mistakes do clinicians make?
Using one monitoring schedule for every peptide
A practice that checks every patient quarterly, whatever the peptide, can miss an early safety signal that a drug-specific schedule would catch. Identify the peptide family first, then use the biomarker list and intervals for that protocol, and note in the chart which protocol you followed.
Comparing to population norms and ignoring the baseline
A creatinine of 1.2 falls in the reference range, but against a baseline of 0.9 it is a 33% rise. Compare each result to the patient's baseline and to the change you expect for that protocol.
Testing too often or too rarely
Monthly labs when quarterly would do adds cost for the patient. Annual labs when the protocol calls for a check at 4 weeks can miss a problem. Follow the interval in your written protocol, shorten it for patients with risk factors, and record why you chose it.
Not defining the red flag for the protocol
If you have not written down which finding means "pause," you may continue therapy when you should stop. A kidney function change on a GLP-1 drug after vomiting or diarrhea is one example. Use the label where one exists, and write down what counts as a red flag for each protocol.
Leaving the reasoning out of the note
"Labs look OK, continuing therapy" does not show how you reached the decision. Write the values, what they indicate, and what you decided.
How do you put this in place in three months?
Month 1: audit your current state
Pull your current monitoring protocols and compare them to the approach in this article.
- Are you monitoring protocol-specific biomarkers, or the same panel for every peptide?
- Do your intervals match the label, where one exists, and your written protocol?
- Are you comparing current labs to baseline?
- Are you documenting clinical reasoning?
The result is a list of your gaps.
Month 2: design protocol-specific monitoring templates
Build a template for each protocol you offer. The author's suggested GLP-1 template:
- Baseline: metabolic panel, CBC, lipids, renal, hepatic
- Week 4: glucose, HbA1c, metabolic panel
- Week 8: repeat the baseline panel
- Week 12 onward: quarterly
- Author's suggested action thresholds: creatinine rise above 15%, ALT above 2 times the upper limit of normal, triglycerides above 300 mg/dL
- Lipase if pancreatitis is suspected
- On a red flag: pause, investigate, refer
Create similar templates for your other protocols, and have your clinical reviewer sign off on every threshold.
Month 3: implement a documentation system
Set up a way to record clinical decisions. It can be paper, an EMR note template, or a dedicated platform. Each record covers the labs reviewed, your interpretation, the decision, patient notification, and follow-up. Write one decision record at every protocol review.
Ongoing: quarterly review and adjustment
Every 3 months, review your protocol decisions and outcomes:
- Did patients with concerning biomarkers improve after a dose adjustment?
- Did you catch red flags early?
- What patterns do you see?
Revise your templates based on what you find.
How does decision documentation help patient care?
Our reasoning is that biomarker-driven monitoring with documented decisions should help practitioners notice safety signals sooner, adjust protocols on evidence, and explain each decision to patients. That is our view. It is not a measured result.
Frequently asked questions
How often should I monitor biomarkers if the patient is stable?
In the author's suggested protocol, once therapy is stable (usually by week 12), move to quarterly monitoring unless the patient has risk factors. For patients over 65 or with comorbidities, the author suggests every 8 weeks. Neither interval comes from a label or guideline.
What if a biomarker is abnormal at baseline? Can I still start the patient?
It depends on the drug. The semaglutide and tirzepatide labels set no renal contraindication and recommend no dose adjustment for renal impairment, but they warn about acute kidney injury from fluid loss. A low baseline eGFR calls for closer follow-up and a clear plan for vomiting or diarrhea. For unapproved peptides there is no label to consult, so document your reasoning either way.
I don't have time to track all these biomarkers. Is this excessive?
You can systematize it. Build a template, use your EMR's note structure, or use a dedicated tool, so each review takes the same form.
Do I need to contact the patient right away if I see a red flag?
In the author's suggested protocol, a red flag (for example, a creatinine rise above 15% or ALT above 2 times the upper limit of normal) warrants contact within 48 hours. Concerning findings can wait for the next scheduled visit, where you discuss and document them. Always record when and how you communicated.
What if my state doesn't specify biomarker monitoring requirements?
No federal monitoring standard exists for these peptides. Use the drug label where there is one (for GLP-1 drugs, the semaglutide and tirzepatide prescribing information), write down your protocol and the reasoning behind it, and have a clinical reviewer approve it. Boards still judge your decisions against the standard of care.
Can I use this framework for telemedicine-only peptide management?
Yes, if the patient's state allows telemedicine prescribing for that drug. Check that state's telehealth rules, including any in-person visit requirement. The patient gets labs drawn locally. Review them promptly, and document when you did.
What should you do next?
Pick one protocol you offer. This month, write its monitoring template and decision-record format, and have your clinical reviewer sign off on the thresholds.
To see how Scriptura's clinical decision support works for prescribers, book a demo. Clinicians verify their license before platform access.
About the author
Educational and regulatory information only
This article is for educational and regulatory information only. It is not legal or medical advice and does not create an attorney-client or clinician-patient relationship. The lab panels, intervals, and thresholds labeled as the author's suggestions are not label or guideline requirements. Confirm current requirements with your state boards and a healthcare attorney licensed in your state before acting.
